News

Funding cuts imperil cancer advances


 

AT THE ASCO ANNUAL MEETING 2013

CHICAGO Publicly funded research in oncology has great potential for reducing the costs of health care. Over the last 10 years, however, funding has dropped off appreciably.

In an exclusive interview at the annual meeting of the American Society of Clinical Oncology, Dr. Monica M. Bertagnolli, group chair of the Alliance for Clinical Trials in Oncology, discusses how cost-saving advances in oncology are being affected by the cut backs.

Recommended Reading

Surgical fellowship directors: General surgery trainees arrive ill prepared
MDedge Hematology and Oncology
ACA understanding: The Policy & Practice Podcast
MDedge Hematology and Oncology
Brand-drug costs rising faster than inflation
MDedge Hematology and Oncology
Forecast warns of urologist shortage
MDedge Hematology and Oncology
Tavenner confirmed as Medicare/Medicaid chief
MDedge Hematology and Oncology
CMS offers $1 billion for health innovators
MDedge Hematology and Oncology
EHR use reaches 'tipping point'
MDedge Hematology and Oncology
CDC urges doctors to help patients quit smoking
MDedge Hematology and Oncology
Palliative care training and associations with burnout in oncology fellows
MDedge Hematology and Oncology
House Republicans proffer SGR fix legislation
MDedge Hematology and Oncology